Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02080195 · ClinicalTrials.gov registry record · Phase 1
Nonmyeloablative Conditioning and Transplantation for Patients With Refractory Systemic Lupus Erythematosus (SLE)
A Phase 1 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT02080195 is a Phase 1 study that was terminated before completion, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 1 participants.
The verdict
NCT02080195, a Phase 1 study, was terminated before completion, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
The main goal of the study is to determine if bone marrow transplant (BMT) from a less specific pool of donors in combination with high dose cyclophosphamide can induce remission of refractory systemic lupus erythematosus.
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG Mycophenolate Mofetil
- DRUG Tacrolimus
- DRUG Rabbit antithymocyte globulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2016-09-13 |
| Est. Completion | 2017-03-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02080195
The ClinicalTrials.gov registry entry for NCT02080195 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT02080195 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02080195 about?
NCT02080195 is a clinical study titled "Nonmyeloablative Conditioning and Transplantation for Patients With Refractory Systemic Lupus Erythematosus (SLE)". The main goal of the study is to determine if bone marrow transplant (BMT) from a less specific pool of donors in combination with high dose cyclophosphamide can induce remission of refractory systemic lupus erythematosus.
What is the current status of trial NCT02080195?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2016-09-13. Estimated completion is 2017-03-29.
What interventions are being tested in trial NCT02080195?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Mycophenolate Mofetil (DRUG), Tacrolimus (DRUG), Rabbit antithymocyte globulin (DRUG).
Who is sponsoring clinical trial NCT02080195?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.